SCP
CRVS icon

Sender Company & Partners’s Corvus Pharmaceuticals CRVS Stock Holding History

Sender Company & Partners’s Portfolio CRVS Stock Details CRVS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-12,995
Closed -$52K – 490
2025
Q2 		$52K Buy
+12,995
New +$47.3K 0.01% 272

Other funds holding CRVS

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ASP
Adams Street Partners Chicago, Illinois $260M AUM 30.38% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
FCMV
Foresite Capital Management VI Larkspur, California $460M AUM 261.77% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Sender Company & Partners's CRVS Position: Q3 2025 in Review

Sender Company & Partners sold out of Corvus Pharmaceuticals (CRVS) in Q3 2025, closing a stake of 12,995 shares — an estimated $52K sold.

Sender Company & Partners first reported a position in CRVS in Q2 2025 and held it in 1 quarter. The position peaked at $52K in Q2 2025. 102 funds tracked by Wall St. Rank hold CRVS as of Q3 2025.

  • Sender Company & Partners reported no remaining Corvus Pharmaceuticals position as of Q3 2025 after selling out during the quarter.
  • Sender Company & Partners sold 12,995 Corvus Pharmaceuticals shares in Q3 2025, an estimated $52K.
  • Sender Company & Partners first reported a position in Corvus Pharmaceuticals in Q2 2025 and held it in 1 quarter.
  • Sender Company & Partners's Corvus Pharmaceuticals position peaked at $52K in Q2 2025.
  • 102 funds tracked by Wall St. Rank held Corvus Pharmaceuticals as of Q3 2025.

Based on Sender Company & Partners's 13F filing for Q3 2025, filed 17 Nov 2025.